Beyond multidrug-resistant tuberculosis in Europe: a TBNET study

• Autor(a) principal: Günther, G
• Data de Publicação: 2015
• Outros Autores: van Leth, F, Altet, N, Dedicoat, M, Duarte, R, Gualano, G, Kunst, H, Muylle, I, Spinu, V, Tiberi, S, Viiklepp, P, Lange, C
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10216/114669
• topic: Multidrug-resistant tuberculosis

The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe. We evaluated second-line drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrug-resistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70% to any second-line injectable drug. Respectively >90% and >80% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43%) and XDR-TB patients (49%).